Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Cellular and Molecular Biology

Abstract 1150: A novel preclinical pancreatic cancer radiation platform: Ptential for high-throughput testing of radiation sensitizers

Richard Tuli, Ariel Zhao, Ashley Leubner, Michael Armour, Erik Tryggestad, Eric Ford, John Wong and Joseph Herman
Richard Tuli
1Johns Hopkins University School of Medicine, Baltimore, MD.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ariel Zhao
1Johns Hopkins University School of Medicine, Baltimore, MD.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ashley Leubner
1Johns Hopkins University School of Medicine, Baltimore, MD.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Armour
1Johns Hopkins University School of Medicine, Baltimore, MD.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erik Tryggestad
1Johns Hopkins University School of Medicine, Baltimore, MD.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Ford
1Johns Hopkins University School of Medicine, Baltimore, MD.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Wong
1Johns Hopkins University School of Medicine, Baltimore, MD.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Herman
1Johns Hopkins University School of Medicine, Baltimore, MD.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM10-1150 Published April 2010
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC

Abstract

Introduction

Small animal research is integral to the development of preclinical therapies, particularly for terminal diseases such as pancreatic cancer. Unfortunately, application of radiation to such models has been limited to non-conformal, single high dose treatments, which are far removed from the highly conformal, fractionated therapies used in the clinic. To help bridge this translational gap, we have developed a pancreatic cancer small animal radiation research platform (SARRP), which when combined with a mouse orthotopic xenograft model, allows focused, image-guided, fractionated irradiation of pancreatic tumors. We propose that this unique translational mouse model can be used to pre-clinically determine how to optimally combine radiation with novel agents to enhance the treatment of patients with unresectable, resectable, and metastatic pancreatic cancer.

Materials and Methods

The SARRP uses a constant voltage X-ray source mounted on a gantry. Robotic stages are used to position the animal. Cone-beam computed tomography (CT) is achieved by rotating the animal between the stationary X-ray source and a flat-panel detector. Dosimetry is measured with radiochromic films. Monte Carlo dose calculations are used for treatment planning. The combination of gantry and robotic stage motions facilitate conformal irradiation. Gold fiducials were placed in the mouse pancreas to allow more reliable targeting. Utilizing anesthetized C57BL mice, an incision was made in the left flank and a 1.5 cm film was sewn to a gold fiducial (1.5 mm). Suture was used to attach the film and fiducial to the pancreas and spleen. Mice were placed in the prone position on the SARRP. Five coplanar beams of radiation were delivered to the pancreas. Radiochromic films were removed, scanned and analyzed.

Results

Cone beam CT planning images with multiple beam arrangement allowed for relative conformality of dose distribution around the pancreas of the C57BL mouse. Spleen and pancreas fiducials were clearly visualized with on-board imaging and analysis of isodose distribution of radiation shows the 70% line (7 Gray) adequately covering the pancreatic fiducial, while effectively sparing the spleen and spinal cord. Analysis of film surrounding the fiducials confirmed that actual dose delivered to pancreas averaged 6.76 Gy (range: 3.91-14.6 Gy, SD 0.40 Gy), while average dose to the spleen was 0.15 Gy (range 0.0-1.39 Gy, SD 0.001 Gy). Mean dose to the pancreas was 21 times greater than that to spleen.

Conclusion

Our studies confirm the ability to deliver precise, potentially fractionated stereotactic radiation therapy to the mouse pancreas, while avoiding normal tissues. We are hopeful that this platform will allow us to closely mimic contemporary human treatment and test combinations of radiation with novel systemic agents and radiosensitizers, thereby accelerating the transition from bench to bedside.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1150.

  • ©2010 American Association for Cancer Research
Back to top
Cancer Research: 70 (8 Supplement)
April 2010
Volume 70, Issue 8 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 1150: A novel preclinical pancreatic cancer radiation platform: Ptential for high-throughput testing of radiation sensitizers
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract 1150: A novel preclinical pancreatic cancer radiation platform: Ptential for high-throughput testing of radiation sensitizers
Richard Tuli, Ariel Zhao, Ashley Leubner, Michael Armour, Erik Tryggestad, Eric Ford, John Wong and Joseph Herman
Cancer Res April 15 2010 (70) (8 Supplement) 1150; DOI: 10.1158/1538-7445.AM10-1150

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 1150: A novel preclinical pancreatic cancer radiation platform: Ptential for high-throughput testing of radiation sensitizers
Richard Tuli, Ariel Zhao, Ashley Leubner, Michael Armour, Erik Tryggestad, Eric Ford, John Wong and Joseph Herman
Cancer Res April 15 2010 (70) (8 Supplement) 1150; DOI: 10.1158/1538-7445.AM10-1150
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Cellular and Molecular Biology

  • Abstract SY34-02: The impact of O2 availability on human cancer
  • Abstract SY29-01: Functions of wild type and mutant p53
  • Abstract SY19-01: Cell to cell variability in the responses of tumor cells to death ligands
Show more 3

Poster Presentations - Proffered Abstracts

  • Abstract LB-236: Risk of tMDS/AML after chemotherapy for first primary lymphoid malignancy, 2000-2013
  • Abstract LB-001: Impact of direct physician engagement with racial/ethnic minorities for oncology clinical trial access and accrual model
  • Abstract LB-107: EV-TRACK: transparent reporting and centralizing knowledge of extracellular vesicles to support the validation of extracellular vesicle biomarkers in cancer research
Show more 3

Poster Presentations - Innovative Technologies 1

  • Abstract 1155: Quantification of circulating tumor cells in peripheral blood using EGFR-targeting gold nanoparticles
  • Abstract 1161: Visualizing lung cancer heterogeneity by color-coding clonal cell subpopulations
  • Abstract 1151: HER2- and EGFR-specific Affiprobes - Novel recombinant optical probes for cell imaging
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement